Trials / Terminated
TerminatedNCT01898598
A Study of Vismodegib With Surgery in Participants With Previously Untreated Basal Cell Carcinoma
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Oral Vismodegib for the Treatment of Basal Cell Carcinoma Preceding Excision by Mohs Micrographic Surgery
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This randomized, double-blind, placebo-controlled study will assess the efficacy and safety of vismodegib with surgery in participants with basal cell carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Participants will receive matching placebo to vismodegib for 12 weeks. |
| DRUG | Vismodegib | Participants will receive vismodegib 150 mg oral capsule once a day for 12 weeks |
Timeline
- Start date
- 2014-01-23
- Primary completion
- 2016-01-26
- Completion
- 2016-01-26
- First posted
- 2013-07-12
- Last updated
- 2017-05-08
- Results posted
- 2017-05-08
Locations
21 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01898598. Inclusion in this directory is not an endorsement.